New opportunities with biologic treatments in pediatric allergic and respiratory diseases

In the last 20 years, the introduction of monoclonal antibodies has dramatically changed allergic diseases. At present, several monoclonal antibodies are approved for treating asthma, atopic dermatitis, chronic spontaneous urticaria, and chronic sinusitis with nasal polyps in children. Biologics hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Tenero, Laura, Piacentini, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305856/
https://www.ncbi.nlm.nih.gov/pubmed/35080293
http://dx.doi.org/10.1111/pai.13617
_version_ 1784752418429337600
author Tenero, Laura
Piacentini, Giorgio
author_facet Tenero, Laura
Piacentini, Giorgio
author_sort Tenero, Laura
collection PubMed
description In the last 20 years, the introduction of monoclonal antibodies has dramatically changed allergic diseases. At present, several monoclonal antibodies are approved for treating asthma, atopic dermatitis, chronic spontaneous urticaria, and chronic sinusitis with nasal polyps in children. Biologics have also changed the management of these diseases in the pediatric population, tending toward personalized medicine based on the type‐2 inflammatory pattern.
format Online
Article
Text
id pubmed-9305856
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93058562022-07-28 New opportunities with biologic treatments in pediatric allergic and respiratory diseases Tenero, Laura Piacentini, Giorgio Pediatr Allergy Immunol Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology In the last 20 years, the introduction of monoclonal antibodies has dramatically changed allergic diseases. At present, several monoclonal antibodies are approved for treating asthma, atopic dermatitis, chronic spontaneous urticaria, and chronic sinusitis with nasal polyps in children. Biologics have also changed the management of these diseases in the pediatric population, tending toward personalized medicine based on the type‐2 inflammatory pattern. John Wiley and Sons Inc. 2022-01-25 2022-01 /pmc/articles/PMC9305856/ /pubmed/35080293 http://dx.doi.org/10.1111/pai.13617 Text en © 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology
Tenero, Laura
Piacentini, Giorgio
New opportunities with biologic treatments in pediatric allergic and respiratory diseases
title New opportunities with biologic treatments in pediatric allergic and respiratory diseases
title_full New opportunities with biologic treatments in pediatric allergic and respiratory diseases
title_fullStr New opportunities with biologic treatments in pediatric allergic and respiratory diseases
title_full_unstemmed New opportunities with biologic treatments in pediatric allergic and respiratory diseases
title_short New opportunities with biologic treatments in pediatric allergic and respiratory diseases
title_sort new opportunities with biologic treatments in pediatric allergic and respiratory diseases
topic Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305856/
https://www.ncbi.nlm.nih.gov/pubmed/35080293
http://dx.doi.org/10.1111/pai.13617
work_keys_str_mv AT tenerolaura newopportunitieswithbiologictreatmentsinpediatricallergicandrespiratorydiseases
AT piacentinigiorgio newopportunitieswithbiologictreatmentsinpediatricallergicandrespiratorydiseases

Ejemplares similares